U.S. market Open. Closes in 5 hours 17 minutes

CARM | Carisma Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for CARM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak.

Valuation (9%)

Company Industry
P/E Ratio (TTM) -0.57 -23.05
PEG Ratio (TTM) -0.05 15.47
P/S Ratio (TTM) 2.00 49.46
P/B Ratio (TTM) 115.08 18.87
P/FCF Ratio (TTM) -0.54 -3.27
Price to 5YR AVG Earnings Ratio -0.01 -3.55
Price to 5YR AVG FCF Ratio -1.04 -9.37

Profitability (25%)

Company Industry
ROA (TTM) -122.18% -5.14%
ROE (TTM) -344.89% 16.69%
Net Profit Margin (TTM) -350.08% -1,583.93%
ROIC 5YR AVG 137.17% 15.15%

Growth (42%)

4QTR AVG 3YR AVG 5YR AVG
EPS 11.64% -10.09% -2,540.73%
Revenue 42.38% 45.41% 25.00%
Net Income 11.26% -63.13% -56.29%
Cash Flow -0.13% -24.85% -193.93%

Health (37%)

Company Industry
Current Ratio (TTM) 3.25 6.13
Quick Ratio (TTM) 3.25 5.85
D/E Ratio (TTM) 10.44 -15.81
Interest Coverage (TTM) -57.08 -1.57
Piotroski F-Score 5 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF -0.03 0.17
Shares Outstanding Growth 5YR AVG 6,287.88% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙